Solution reagent kit HyperCap DS NHL

for researchclinicalFree Circulating

The KAPA HyperCap Design Share (DS) non-Hodgkin lymphoma (NHL) panel enables highly sensitive detection and longitudinal analysis of ctDNA in blood-derived NHL samples for research use purposes. Existing methods such as the radiological and nuclear imaging methods are unable to provide key information on clonal evolution and minimal residual disease (MRD). Cell-free circulating tumor DNA (cfDNA/ctDNA), typically assessed using targeted deep sequencing, has emerged as an important non-invasive and highly sensitive biomarker in the monitoring of NHL patient status.2,3 To unlock the full potential of ctDNA as a biomarker more research needs to be done to better understand where it can make the most impact. Now clinical researchers have the flexibility to develop their in-house workflows using the KAPA HyperCap DS NHL panel along with the robust KAPA HyperCap workflows5 and customizable bioinformatics. Features and benefits of the KAPA HyperCap DS NHL panel Insights from ctDNA NHL research now within your reach - Pioneer advances in NHL research by using a unique panel developed for ctDNA monitoring. Unique panel design used in a large pivotal study - Leverage a panel based on years of rigorous research and panel design that was used in the POLARIX study to validate ctDNA as a prognostic biomarker. Simplified and reliable NHL research workflows - Utilize robust and streamlined KAPA workflows with the new KAPA HyperCap DS NHL panel and customizable open-source bioinformatics analysis.